Table 1 Baseline information of the included studies.
Study | Method | Origin | Included (M/F) | Age (year) (M ± SD) | Mean Age of Onset Illness (year) | Duration of Illness (years) | Interventions (drug/dosage/frequency) | Outcomes measurements | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
T | C | T | C | T | C | T | C | T | C | ||||
Luo.et al.25 | 16-week, double-blind, parallel-group, multi-center | Inpatient | 304 (248/56) | 208 (170/38) | 37.9 ± 10.4 | 36.9 ± 8.7 | U | U | 8.9 ± 4.7 | 8.4 ± 4.7 | Antipsychotic (N/A); Shuxuening/40–120 mg/tid | antipsychotic (N/A); placebo/40–120 mg/tid | BPRS/SANS/RSESE |
Hou.et al.27 | 12-week, parallel-group | Inpatient | 35 (23/12) | 35 (24/11) | 36.9 ± 6.7 | 37.1 ± 6.2 | U | U | 6.4 ± 4.8 | 6.6 ± 3.7 | Clozapine (N/A); promoting blood circulation formul once daily | Clozapine (N/A) | PANSS/TESS |
Li et al.23 | 12-week, parallel-group | Inpatient | 35 (23/12) | 35 (24/11) | 36.9 ± 6.7 | 37.1 ± 6.2 | U | U | 6.4 ± 4.8 | 6.6 ± 3.7 | Clozapine (N/A); promoting blood circulation formul once daily | Clozapine (N/A) | PANSS/TESS |
Qin et al.28 | 12-week, double-blind, parallel-group | Inpatient | 50 (28/22) | 50 (26/24) | 39.7 ± 10.8 | 39.4 ± 10.6 | U | U | 9.2 ± 6.5 | 9.9 ± 7.8 | Risperidone/4.8 ± 0.8 mg/d; Jieyu Anshen Decoction once daily | Risperidone/4.8 ± 0.8 mg/d; placebo once daily | PANSS/TESS |
Zeng. et al.29 | 12-week, parallel-group | Inpatient | 50 (22/28) | 50 (24/26) | 45.7 ± 15.6 | 45.4 ± 16.2 | U | U | 10.4 ± 3.5 | 9.9 ± 3.8 | Aripiprazole/14.4 ± 5.5 mg/d; Jieyu Anshen Decoction once daily | Aripiprazole/18.6 ± 6.8 mg/d | PANSS/TESS |
Chen et al.17 | 8-week, double-blind, parallel-group, multicenter | Outpatient, Inpatient | 100 (49/51) | 100 (52/48) | 33.4 ± 10.5 | 32.5 ± 9.1 | 24 ± 7 | 24 ± 9 | 9 ± 3 | 9 ± 4 | Risperidone(N/A);warm-supplement kidney yang capsule/0.9 g/tid | Risperidone(N/A);placebo capsule/0.9 g/tid | PANSS/SAPS/SANS/WCST/SDSS |
Liu et al.22 | 8-week, parallel-group | Inpatient | 56 (33/23) | 52 (30/22) | 36.67 ± 10.08 | 36.11 ± 10.52 | U | U | N/A | N/A | Antipsychotic(N/A); Xuefu Zhuyu Dection once daily | Antipsychotic (N/A) | PANSS/CGI/TESS |
Wang et al20 | 8-week, parallel-group | Inpatient | 86 (52/34) | 74 (45/29) | 36.26 ± 12.24 | 31.21 ± 16.52 | U | U | N/A | N/A | Antipsychotic(N/A); Shunqi Daotang Decotion or Yangxin Decotion or Xuefu Zhuyu Decotiononce daily | Antipsychotic(N/A) | PANSS/TESS |
Luo. et al.26 | 12-week, double-blind, parallel-group | Inpatient | 40 (NA) | 40 (NA) | N/A | N/A | U | U | N/A | N/A | Quetiapine/345.5 ± 65.5 mg/d; Qingxintang | Quetiapine/355.5 ± 75.5 mg/d | PANSS/TESS |
Yang. et al.24 | 8-week, parallel-group | Outpatient, Inpatient | 20 (12/8) | 20 (9/11) | 44 ± 3.6 | 37.8 ± 6.2 | U | U | 6.8 ± 1.4 | 7.4 ± 2.6 | Risperidon/4–6 mg/d; Shugan Jieyu Capsule/2 tablets/bid | Risperidone/4–6 mg/d | PANSS |
Han. et al.201424 | 12-week, parallel-group | Inpatient | 60 (27/33) | 60 (26/34) | 46.25 ± 15.86 | 46.19 ± 15.22 | U | U | 10.73 ± 3.64 | 10.55 ± 3.63 | Aripiprazole/15–30 mg/d; Jieyu Anshen Decoction once daily | Aripiprazole/15–30 mg/d | PANSS/TESS |
Wang. et al.19 | 12-week, double-blind, parallel-group | Inpatient | 25 (11/14) | 27 (11/16) | 38.44 ± 2.28 | 42.15 ± 2.34 | U | U | 7.74 ± 5.16 | 6.86 ± 5.59 | Risperidone/6 mg/d; Eryin Jian 6 g/bid | Risperidone/6 mg/d; placebo/6 g/bid | PANSS/TESS |
Wang et al. 21 | 12-week, double-blind, parallel-group | Inpatient | 50 (26/24) | 50 (25/25) | 38.5 ± 10.6 | 38.4 ± 10.7 | U | U | 8.4 ± 6.3 | 8.5 ± 7.8 | Aripiprazole;Wenyang JianpiHuoxue Decotiononce daily | Aripiprazole/15–20 mg/d | BPRS/SANS/TESS |
Miyaoka et al.18 | 4-week, multicenter, double-blind | Inpatient | 56 (34/22) | 61 (39/22) | 46.7 ± 9.8 | 46.3 ± 9.6 | U | U | 24.0 ± 10.4 | 23.6 ± 10.2 | Chlorpromazine/2037.2 ± 2046.8 mg/day; yokukansan/2.5 g/tid | Chlorpromazine/1925.8 ± 2040.2 mg/day; placebo capsule/0.10 g/tid | PANSS/CGI/GAF/DIEPSS |
